Assessment of Antimicrobial Utilization among Cancer Patients with Febrile Neutropenia at the Lebanese Hospitals

被引:0
|
作者
Cherri, Sarah [1 ]
Malaeb, Diana [1 ,2 ]
Shouman, Lamis [1 ]
Fahs, Iqbal [1 ]
Hallit, Rabih [3 ,4 ,5 ]
Hallit, Souheil [3 ,6 ,7 ]
Malaeb, Bassem [8 ]
Salameh, Pascale [9 ,10 ,11 ,12 ]
机构
[1] Lebanese Int Univ, Sch Pharm, Beirut, Lebanon
[2] Gulf Med Univ, Coll Pharm, Ajman, U Arab Emirates
[3] Holy Spirit Univ Kaslik, Sch Med & Med Sci, Jounieh, Lebanon
[4] Bellevue Med Ctr, Dept Infect Dis, Mansourieh, Lebanon
[5] Univ Hosp Ctr, Notre Dame Secours, Dept Infect Dis, Byblos, Lebanon
[6] Effat Univ, Coll Human, Psychol Dept, Jeddah 21478, Saudi Arabia
[7] Psychiat Hosp Cross, Res Dept, Jal Eddib, Lebanon
[8] Dr Sulaiman Al Habib Med Grp, Dubai, U Arab Emirates
[9] Inst Natl Sante Publ Epidemiol Clin & Toxicol, INSPECT LB, Beirut, Lebanon
[10] Lebanese Amer Univ, Sch Med, Byblos, Lebanon
[11] Univ Nicosia, Sch Med, Dept Primary Care & Populat Hlth, Nicosia, Cyprus
[12] Lebanese Univ, Fac Pharm, Hadat, Lebanon
关键词
Antibiotic; antifungal; antiviral; febrile neutropenia; evaluation; hospital; INFECTIOUS-DISEASES SOCIETY; BLOOD-STREAM INFECTIONS; EMPIRICAL-TREATMENT; FEVER; EPIDEMIOLOGY; THERAPY; RISK; GUIDELINES; MANAGEMENT; CEFEPIME;
D O I
10.2174/1574886317666220620153115
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Febrile neutropenia is a prevalent oncologic complication. Initiating rapid treatment with empirical antimicrobials in febrile neutropenia patients reduces mortality due to infections. Objectives: The study aims to evaluate antimicrobial utilization among FN patients in Lebanon in terms of drug choice, dose, and duration of the treatment. This is a retrospective, multicenter, observational study conducted at three different Lebanese university hospitals (in which the Infectious Diseases Society of America ( IDSA) guidelines are adopted), between February 2014 and May 2017. Methods: Adult cancer patients aged 18 years and older with febrile neutropenia were included in the study. Using the IDSA guidelines as a reference, patients were assessed whether they received the antimicrobial regimen inconsistent with the IDSA reference or not. Statistical analysis was performed using the Statistical Package for the Social Science software (SPSS version 22.0). The adherence to guidelines for the indication and doses of antibiotics and anti-fungal in patients with febrile neutropenia. Results: A total of 124 patients with a mean age of 54.43 +/- 17.86 years were enrolled in the study. Leukemia (29.7%) was the most prevalent cancer and the most common infection was sepsis (20.2%). Combination antibiotic lactams are the most prescribed antibiotics (86.8%). Only 94 (86.23%) patients were given the antibiotic therapy appropriate for choice, dose, and duration. Empirical antifungal therapy was initiated in 63.7% of the patients and fluconazole was the most used antifungal (36.3%). In contrast to antibiotics, the majority of antifungal choices were not selected according to the recommendations and they were considered inappropriate for doses and the required treatment duration as proposed by (IDSA). Fifty-eight percent of patients received antivirals, even though it is not recommended as empirical treatment. Conclusion: In conclusion, this study reveals a non-consistent antimicrobial utilization practice at the involved sites concerning FN treatment. Inappropriateness was encountered in drug selection, dose, and duration of treatment with antifungals and antivirals.
引用
收藏
页码:496 / 503
页数:8
相关论文
共 50 条
  • [41] Cefepime monotherapy for febrile neutropenia in patients with lung cancer
    Saito, Hiroshi
    Takahashi, Kosuke
    Okuno, Motoyasu
    Saka, Hideo
    Imaizumi, Kazuyoshi
    Hasegawa, Yoshinori
    Tanikawa, Yoshimasa
    Yamamoto, Masashi
    Taniguchi, Hiroyuki
    Shindoh, Joe
    Suzuki, Ryujiro
    Shimokata, Kaoru
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2014, 20 (5-6) : 365 - 369
  • [42] Identification of cancer patients at high risk of febrile neutropenia
    Scott, S
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2002, 59 : S16 - S19
  • [43] Risk of mortality in patients with cancer experiencing febrile neutropenia
    Lyman, G. H.
    Michels, S. L.
    Tomic, K. E.
    Yu, J.
    Reynolds, M. W.
    Barron, R. L.
    EJC SUPPLEMENTS, 2009, 7 (02): : 176 - 177
  • [44] Management of infection and febrile neutropenia in patients with solid cancer
    Virizuela, J. A.
    Carratala, J.
    Aguado, J. M.
    Vicente, D.
    Salavert, M.
    Ruiz, M.
    Ruiz, I.
    Marco, F.
    Lizasoain, M.
    Jimenez-Fonseca, P.
    Gudiol, C.
    Cassinello, J.
    Carmona-Bayonas, A.
    Aguilar, M.
    Cruz, J. J.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2016, 18 (06): : 557 - 570
  • [45] Febrile neutropenia in cancer patients: management in the emergency room
    Rivera-Salgado, Daniel
    Valverde-Munoz, Kathia
    Avila-Aguero, Maria L.
    REVISTA CHILENA DE INFECTOLOGIA, 2018, 35 (01): : 62 - 71
  • [46] Author Correction: Procalcitonin Guiding Antimicrobial Therapy Duration in Febrile Cancer Patients with Documented Infection or Neutropenia
    Hanine El Haddad
    Anne-Marie Chaftari
    Ray Hachem
    Majd Michael
    Ying Jiang
    Ammar Yousif
    Sammy Raad
    Mary Jordan
    Patrick Chaftari
    Issam Raad
    Scientific Reports, 8
  • [47] Management of Breast Cancer Patients with Chemotherapy-Induced Neutropenia or Febrile Neutropenia
    Fontanella, Caterina
    Bolzonello, Silvia
    Lederer, Bianca
    Aprile, Giuseppe
    BREAST CARE, 2014, 9 (04) : 239 - 245
  • [48] Non-cancer febrile neutropenia in children: pathogens, antimicrobial susceptibilities, and outcomes
    Radwan, Radwa Abdel-Raheem
    Youssry, Ilham
    Afifi, Rasha Abdelraouf Abdelzaiz
    Banna, Afaf Mohamed Samy El
    Balah, Mariam Mahmoud Mohammed
    Mohammed, Eman Abdel El Raouf
    EGYPTIAN PEDIATRIC ASSOCIATION GAZETTE, 2024, 72 (01)
  • [49] Predictors of Febrile Neutropenia Among Cancer Patients Receiving Myelosuppressive Chemotherapy in US Clinical Practice
    Lyman, Gary H.
    Richert-Boe, Kathryn
    Lamerato, Lois
    Kaur, Manpreet
    Shah, Neel
    Lawrence, Tatiana
    Sundaresan, Devi
    Silvia, Amanda
    Hanau, Ahuva
    Weycker, Derek
    BLOOD, 2019, 134
  • [50] Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions
    Xiao Jun Wang
    Alexandre Chan
    Current Oncology Reports, 2017, 19